Abstract
Objective: Purpose of this Italian economic analysis was to estimate the cost-effectiveness of dasatinib (100 mg/day) versus high-dose (800 mg/day) imatinib (HDI), in CP-CML patients, in the perspective of the Italian National Healthcare System (NHS).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
